EX-99.1 2 id8663ex991.htm EXHIBIT 99.1

Exhibit 99.1

Message

Contact: Merilee Raines, Chief Financial Officer, 1-207-556-8155

FOR IMMEDIATE RELEASE

IDEXX Laboratories Announces Fourth Quarter Results

WESTBROOK, Maine, January 26, 2007 — IDEXX Laboratories, Inc. (NASDAQ: IDXX), today reported that revenue for the fourth quarter of 2006 increased 15% to $192.2 million from $167.0 million for the fourth quarter of 2005. Adjusted for the impacts of acquisitions and changes in foreign currency exchange rates, revenue for the fourth quarter of 2006 increased 11% over the same period of the prior year. Earnings per diluted share (“EPS”) for the quarter ended December 31, 2006 increased 25% to $0.75 from $0.60 for the same period in the prior year.

          Non-GAAP adjusted diluted EPS for the fourth quarter were $0.68, an increase of 6% compared to non-GAAP adjusted diluted EPS for the same period of the prior year. Non-GAAP adjusted diluted EPS including share-based compensation expense was $0.62. Management believes adjusted diluted EPS is a useful non-GAAP financial measure to evaluate the results of ongoing operations, excluding significant specified items, period over period, and therefore believes that investors may find this information useful in addition to the GAAP results. The accompanying financial table provides additional information and reconciles these non-GAAP measures to earnings per diluted share.

          “We have wrapped up a strong year of organic revenue growth, investment in the new product pipeline, and strategic acquisitions across our business portfolio, all of which position us extremely well for continued growth in 2007 and 2008. In particular, I am pleased with the outlook we see for continued success in the companion animal market,” said Jonathan Ayers, Chairman and Chief Executive Officer.

          “We are making excellent progress on the growth and further development of our bench-top line of instruments and proprietary consumables for the companion animal market. We expect to launch our next generation chemistry analyzer, Catalyst Dx™, in January of 2008 along with a second platform, SNAPshot Dx™, which will augment the immunodiagnostic capability of the IDEXX VetLab® suite of instruments. Through these launches, we expect to take the pet-side diagnostic capability of the IDEXX VetLab suite to a whole new level of performance and value.”

          Companion Animal Group (“CAG”) revenue for the fourth quarter of 2006 increased 15% to $157.0 million from $135.9 million for the fourth quarter of 2005 due to higher sales in all CAG product and service categories, with the largest growth in revenue from laboratory and consulting services. Incremental sales from businesses acquired since January 2005, consisting primarily of veterinary reference laboratories, a digital radiography business, and intellectual property and distribution rights of a veterinary diagnostics business, contributed 2% to CAG revenue growth. The favorable impact of foreign currency exchange rates also contributed 2% to CAG revenue growth.


IDEXX Announces Fourth Quarter Results
January 26, 2007
Page 2 of 13

          Water segment revenue for the fourth quarter increased 1% to $14.7 million from $14.6 million for the fourth quarter of 2005 due to the favorable impact of foreign currency exchange rates, which increased Water revenue growth by 3%, and, to a lesser extent, higher average unit sales prices. These favorable impacts were partly offset by lower sales volume.

          Food Diagnostics Group (“FDG”) revenue for the fourth quarter increased 25% to $20.5 million from $16.4 million for the fourth quarter of 2005 primarily due to higher worldwide livestock diagnostics sales volume, particularly of the IDEXX HerdChek® test for transmissible spongiform encephalopathies. The favorable impact of foreign currency exchange rates increased FDG revenue growth by 6%.

Full-year results

          Revenue for the year ended December 31, 2006 increased 16% to $739.1 million from $638.1 million for the same period in 2005. Incremental sales from businesses acquired since the beginning of 2005 added 2% to revenue growth. Changes in foreign currency exchange rates did not have a significant impact on the reported revenue growth rate. Revenue for the year ended December 31, 2006, adjusted for the impacts of acquisitions and foreign currency exchange rates, increased 14%.

          Earnings per diluted share for 2006 increased 23% to $2.84 from $2.30 for the same period in the prior year. Non-GAAP adjusted diluted EPS for the year ended December 31, 2006 were $2.93, an increase of 23% compared to non-GAAP adjusted diluted EPS for 2005. Non-GAAP adjusted diluted EPS including share-based compensation expense was $2.67. The accompanying financial table provides additional information and reconciles these non-GAAP measures to earnings per diluted share.

          Companion Animal Group (“CAG”) revenue for the year ended December 31, 2006 increased 16% to $606.3 million from $520.8 million due to higher sales in all CAG product and service categories, with the largest growth in revenue from laboratory and consulting services. Incremental sales from businesses acquired since the beginning of 2005, consisting primarily of veterinary reference laboratories, a digital radiography business, and intellectual property and distribution rights of a veterinary diagnostics business, contributed 2% to CAG revenue growth. Changes in foreign currency exchange rates did not have a significant impact on the CAG revenue growth rate.

          Water segment revenue for the year ended December 31, 2006 increased 3% to $58.5 million from $56.8 million primarily due to higher sales volume in the Americas and Europe and, to a lesser extent, to higher average unit sales prices. The favorable impact of foreign currency exchange rates increased the Water revenue growth rate by 1%. 


IDEXX Announces Fourth Quarter Results
January 26, 2007
Page 3 of 13

          Food Diagnostics Group (“FDG”) revenue for the year ended December 31, 2006 increased 23% to $74.3 million from $60.5 million for the same period in 2005. This increase is primarily due to higher worldwide sales volume of livestock diagnostics. The favorable impact of foreign currency exchange rates increased FDG revenue growth by 1%.

Additional operating results for the fourth quarter

          Gross profit for the fourth quarter of 2006 increased $11.4 million, or 13%, to $96.3 million from $84.9 million for 2005. As a percentage of revenue, gross profit decreased to 50% from 51% primarily due to proportionately higher sales of laboratory and consulting services and instruments, which are sold at lower gross profit rates than certain other products, and to the combined net unfavorable impact of changes in foreign currency rates on foreign exchange hedge contracts and on sales denominated in those foreign currencies. These unfavorable impacts on the gross profit percentage were partly offset by the lower cost of slides sold for use in IDEXX VetTest® chemistry analyzers.

          Research and development (“R&D”) expense for the quarter was $14.0 million compared to $10.6 million for the fourth quarter of 2005. As a percentage of revenue, R&D expense increased to 7.3% from 6.4% for the same period in 2005.

          Selling, general and administrative (“SG&A”) expense for the quarter was $52.8 million, or 27% of revenue, compared to $44.1 million, or 26% of revenue, in the fourth quarter of 2005. Increased SG&A expense was due primarily to higher personnel-related costs due, in part, to expanded worldwide sales, customer service and marketing headcount; share-based compensation expense, including the impact of SFAS No. 123(R) which was adopted on January 1, 2006; and higher spending on information technology and other general support functions.

Acquisition of Institut Pourquier

          The Company also announced today that it has entered into an agreement to acquire all of the outstanding shares of Institut Pourquier. Based in Montpelier, France, Institut Pourquier is a leading provider of production animal diagnostic products with a strong European market presence and a product portfolio that is complementary to the Company’s existing production animal products. In 2006 Institut Pourquier had sales of approximately $7.5 million. The Company expects to complete the acquisition during the first quarter of 2007. 


IDEXX Announces Fourth Quarter Results
January 26, 2007
Page 4 of 13

Outlook

          The Company offers the following revised guidance for the full year of 2007, which reflects the estimated impacts of the previously announced acquisitions of Central Laboratory for Veterinarians Ltd., which closed in November 2006, and the Critical Care Division of Osmetech plc, which is expected to close on or around January 31, 2007, as well as the anticipated acquisition of Institut Pourquier, which is expected to close during the first quarter of 2007:

 

•

Revenue is expected to be $860 to $870 million, including $28 to $30 million of revenue attributable to these acquisitions.

 

 

 

 

•

Diluted earnings per share are expected to be $2.90 to $2.98, which reflects a dilutive impact of approximately $0.14 per diluted share attributable to these acquisitions, of which approximately $0.04 per diluted share is attributable to the acquisition of Institut Pourquier.

Conference Call and Webcast Information

          IDEXX Laboratories will be hosting a conference call today at 9:00 a.m. (eastern) to discuss its fourth quarter results. To participate in the conference call, dial 800-475-3716 or 719-457-2727 and reference confirmation code 1704816. An audio replay will be available through February 2 by dialing 719-457-0820 and referencing replay code 1704816.

          The call will also be available via live or archived Webcast on the IDEXX Laboratories’ web site at www.idexx.com.

About IDEXX Laboratories

          IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice management systems and pharmaceuticals. IDEXX products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs more than 3,500 people and offers products to customers in over 100 countries.


IDEXX Announces Fourth Quarter Results
January 26, 2007
Page 5 of 13

Note Regarding Forward-Looking Statements

This press release contains statements about the Company’s business prospects and estimates of the Company’s financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company’s sales and marketing activities; the Company’s ability to develop, license or obtain rights to new technologies; the Company’s ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company’s products; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the Company’s products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of our products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company’s inventories; the Company’s ability to manufacture complex biologic products; the effects of operations outside the U.S., including  from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005, and on  the Quarterly Report on Form 10-Q for the quarter ended September 30, 2006, in the section captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”


IDEXX Announces Fourth Quarter Results
January 26, 2007
Page 6 of 13

IDEXX Laboratories, Inc. and Subsidiaries
Consolidated Statement of Operations
Amounts in thousands except per share data (Unaudited)

 

 

 

 

 

Three Months Ended

 

Twelve Months Ended

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,
2006

 

December 31,
2005

 

December 31,
2006

 

December 31,
2005

 

 

 

Revenue:

 

 

Revenue

 

$

192,209

 

$

166,970

 

$

739,117

 

$

638,095

 

Expenses and Income:

 

 

Cost of revenue

 

 

95,940

 

 

82,054

 

 

359,588

 

 

315,195

 

 

 

 

 

 

Gross profit

 

 

96,269

 

 

84,916

 

 

379,529

 

 

322,900

 

 

 

 

Sales and marketing

 

 

31,214

 

 

26,769

 

 

115,882

 

 

101,990

 

 

 

 

General and administrative

 

 

21,634

 

 

17,327

 

 

82,097

 

 

64,631

 

 

 

 

Research and development

 

 

13,951

 

 

10,636

 

 

53,617

 

 

40,948

 

 

 

 

 

 

Income from operations

 

 

29,470

 

 

30,184

 

 

127,933

 

 

115,331

 

 

 

 

Interest income, net

 

 

845

 

 

849

 

 

2,817

 

 

3,141

 

 

 

 

 

 

Income before provision for income taxes and partner’s interest

 

 

30,315

 

 

31,033

 

 

130,750

 

 

118,472

 

 

 

 

Provision for income taxes

 

 

5,643

 

 

11,137

 

 

37,224

 

 

40,670

 

 

 

 

Partner’s share of consolidated loss

 

 

—  

 

 

(131

)

 

(152

)

 

(452

)

 

 

Net Income:

 

 

Net income

 

$

24,672

 

$

20,027

 

$

93,678

 

$

78,254

 

 

 

 

 

 

Earnings per share: Basic

 

$

0.79

 

$

0.63

 

$

2.98

 

$

2.41

 

 

 

 

 

 

Earnings per share: Diluted

 

$

0.75

 

$

0.60

 

$

2.84

 

$

2.30

 

 

 

 

 

 

Shares outstanding: Basic

 

 

31,261

 

 

32,032

 

 

31,433

 

 

32,521

 

 

 

 

 

 

Shares outstanding: Diluted

 

 

32,736

 

 

33,627

 

 

32,954

 

 

34,055

 

 

 

IDEXX Laboratories, Inc. and Subsidiaries
Key Operating Information (Unaudited)

 

 

 

 

 

Three Months Ended

 

Twelve Months Ended

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,
2006

 

December 31,
2005

 

December 31,
2006

 

December 31,
2005

 

 

 

Key Operating

 

 

Gross profit

 

 

50.1

%

 

50.9

%

 

51.3

%

 

50.6

%

Ratios (as a percentage of revenue):

 

 

Sales, marketing, general and administrative expense

 

 

27.5

%

 

26.4

%

 

26.8

%

 

26.1

%

 

 

 

Research and development expense

 

 

7.3

%

 

6.4

%

 

7.2

%

 

6.4

%

 

 

 

 

 

Income from operations

 

 

15.3

%

 

18.1

%

 

17.3

%

 

18.1

%

 

 

International

 

 

International revenue (in thousands)

 

$

70,590

 

$

59,153

 

$

260,945

 

$

219,530

 

Revenue:

 

 

 

 

International revenue as percentage of total revenue

 

 

36.7

%

 

35.4

%

 

35.3

%

 

34.4

%

 

 


IDEXX Announces Fourth Quarter Results
January 26, 2007
Page 7 of 13

IDEXX Laboratories, Inc. and Subsidiaries
Non-GAAP Financial Measures
Amounts in thousands except per share data (Unaudited)

 

 

Three Months Ended

 

 

 

 

 

 

Gross Profit

 

Income from
Operations

 

Net Income

 

Earnings per Share
Diluted

 

 

 

 

 

 

 

 

 

Dec. 31,
2006

 

Dec. 31,
2005

 

Dec. 31,
2006

 

Dec. 31,
2005

 

Dec. 31,
2006

 

Dec. 31,
2005

 

Dec. 31,
2006

 

Dec. 31,
2005

 

 

GAAP measurement

 

$

96,269

 

$

84,916

 

$

29,470

 

$

30,184

 

$

24,672

 

$

20,027

 

$

0.75

 

$

0.60

 

Specified items:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition-related integration costs & investment impairment (1)

 

 

82

 

 

57

 

 

467

 

 

928

 

 

311

 

 

618

 

 

0.01

 

 

0.02

 

Discrete income tax expense (benefit) (2)

 

 

—  

 

 

—  

 

 

—  

 

 

—  

 

 

(4,830

)

 

992

 

 

(0.15

)

 

0.03

 

 

 

 

 

 

 

subtotal (4)

 

 

96,351

 

 

84,973

 

 

29,937

 

 

31,112

 

 

20,153

 

 

21,637

 

 

0.62

 

 

0.64

 

Share-based compensation expense (3)

 

 

450

 

 

—  

 

 

2,653

 

 

—  

 

 

2,168

 

 

—  

 

 

0.07

 

 

—  

 

 

 

 

 

Non-GAAP comparative measurements(4)

 

$

96,801

 

$

84,973

 

$

32,590

 

$

31,112

 

$

22,321

 

$

21,637

 

$

0.68

 

$

0.64

 

 

 

 

 

We use these supplemental non-GAAP financial measures to evaluate the Company’s comparative financial performance. The specified items that are excluded in these non-GAAP measures are actual charges that impact net income and cash flows, however, we believe that it is useful to evaluate our core business performance period over period excluding these specified items, in addition to relying upon GAAP financial measures.

(1) We believe that the change from period to period due to specific acquisition-related purchase accounting and integration costs is not representative of ongoing operations and is not indicative of future performance. Specific acquisition-related discrete costs do not include amortization expense related to acquired intangible assets. Discrete items for 2006 also include a write-down of an equity investment in one of our technology licensors. We believe that the investment write-down is infrequent and is not representative of ongoing operations; IDEXX holds no other equity investments.

 

(2) We believe that certain significant discrete income tax items create impacts on financial measures that are not indicative of future performance because the items are not likely to recur within a reasonable period. For 2006, the separately identified discrete income tax benefit was due to a reduction in previously accrued taxes in connection with the resolution of an Internal Revenue Service income tax audit for 2003 and 2004 in advance of the expiration of the statutes of limitations. For 2005, income tax expense on the repatriation of foreign earnings under the American Jobs Creation Act is separately identified as a discrete expense.

 

(3) We adjusted 2006 GAAP financial results to exclude the after-tax impact of share-based compensation expense, except for the impact of deferred stock units issued under our Director Compensation Plan and our Executive Deferred Compensation Plan that do not have vesting conditions, in order to evaluate the Company’s performance relative to 2005 financial results. We do not consider the pro forma 2005 financial results that are included in our Annual Report on Form 10-K and quarterly reports on Form 10-Q to be reasonably comparable to 2006 financial results with respect to the impact of share-based compensation expense due to several factors, including changes in 2006 in the types, terms and total fair value of share-based compensation awards; changes in the timing of expense recognition for 2006 awards; and differences between periods in income tax benefits.

 

(4) The sum of the individual items may not equal the non-GAAP measurement due to rounding of the individual items in this presentation.


IDEXX Announces Fourth Quarter Results
January 26, 2007
Page 8 of 13

IDEXX Laboratories, Inc. and Subsidiaries
Non-GAAP Financial Measures
Amounts in thousands except per share data (Unaudited)

 

 

Twelve Months Ended

 

 

 

 

 

 

Gross Profit

 

Income from
Operations

 

Net Income

 

Earnings per Share
Diluted

 

 

 

 

 

 

 

 

 

Dec. 31,
2006

 

Dec. 31,
2005

 

Dec. 31,
2006

 

Dec. 31,
2005

 

Dec. 31,
2006

 

Dec. 31,
2005

 

Dec. 31,
2006

 

Dec. 31,
2005

 

 

GAAP measurement

 

$

379,529

 

$

322,900

 

$

127,933

 

$

115,331

 

$

93,678

 

$

78,254

 

$

2.84

 

$

2.30

 

Specified items:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition-related integration costs & investment impairment (1)

 

 

82

 

 

981

 

 

467

 

 

2,830

 

 

311

 

 

1,886

 

 

0.01

 

 

0.05

 

Discrete income tax expense (benefit) (2)

 

 

—  

 

 

—  

 

 

—  

 

 

—  

 

 

(6,111

)

 

992

 

 

(0.19

)

 

0.03

 

 

 

 

 

 

 

subtotal (4)

 

 

379,611

 

 

323,881

 

 

128,400

 

 

118,161

 

 

87,878

 

 

81,132

 

 

2.67

 

 

2.38

 

Share-based compensation expense (3)

 

 

1,671

 

 

—  

 

 

10,657

 

 

—  

 

 

8,812

 

 

—  

 

 

0.27

 

 

—  

 

 

 

 

 

Non-GAAP comparative measurements(4)

 

$

381,282

 

$

323,881

 

$

139,057

 

$

118,161

 

$

96,690

 

$

81,132

 

$

2.93

 

$

2.38

 

 

 

 

 

We use these supplemental non-GAAP financial measures to evaluate the Company’s comparative financial performance. The specified items that are excluded in these non-GAAP measures are actual charges that impact net income and cash flows, however, we believe that it is useful to evaluate our core business performance period over period excluding these specified items, in addition to relying upon GAAP financial measures.

 

(1) We believe that the change from period to period due to specific acquisition-related purchase accounting and integration costs is not representative of ongoing operations and is not indicative of future performance. Specific acquisition-related discrete costs do not include amortization expense related to acquired intangible assets. The discrete integration costs incurred in 2005 included costs associated with the consolidation of our European production animal diagnostics operations in Bern, Switzerland. Discrete items for 2006 also include a write-down of an equity investment in one of our technology licensors. We believe that the investment write-down is infrequent and is not representative of ongoing operations; IDEXX holds no other equity investments.

 

(2) We believe that certain significant discrete income tax items create impacts on financial measures that are not indicative of future performance because the items are not likely to recur within a reasonable period. For 2006, the separately identified discrete income tax benefits were composed of a tax benefit of $0.15 per diluted share due to a reduction in previously accrued taxes in connection with the resolution of an Internal Revenue Service income tax audit for 2003 and 2004 in advance of the expiration of the statutes of limitations, a tax benefit of $0.03 per diluted share due to a reduction of previously recorded international deferred tax liabilities as a result of obtaining certain multi-year tax incentives, and a tax benefit of $0.01 per diluted share due to the release of a valuation allowance on international deferred tax assets as a result of a subsidiary demonstrating consistent sustained profitability. For 2005, income tax expense on the repatriation of foreign earnings under the American Jobs Creation Act is separately identified as a discrete expense.

 

(3) We adjusted 2006 GAAP financial results to exclude the after-tax impact of share-based compensation expense, except for the impact of deferred stock units issued under our Director Compensation Plan and our Executive Deferred Compensation Plan that do not have vesting conditions, in order to evaluate the Company’s performance relative to 2005 financial results. We do not consider the pro forma 2005 financial results that are included in our Annual Report on Form 10-K and quarterly reports on Form 10-Q to be reasonably comparable to 2006 financial results with respect to the impact of share-based compensation expense due to several factors, including changes in 2006 in the types, terms and total fair value of share-based compensation awards; changes in the timing of expense recognition for 2006 awards; and differences between periods in income tax benefits.

 

(4) The sum of the individual items may not equal the non-GAAP measurement due to rounding of the individual items in this presentation.


IDEXX Announces Fourth Quarter Results
January 26, 2007
Page 9 of 13

IDEXX Laboratories, Inc. and Subsidiaries
Segment Information
Amounts in thousands (Unaudited)

 

 

 

 

 

Three Months Ended

 

Twelve Months Ended

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,
2006

 

December 31,
2005

 

December 31,
2006

 

December 31,
2005

 

 

 

Revenue:

 

 

Companion Animal Group

 

$

156,995

 

$

135,942

 

$

606,319

 

$

520,830

 

 

 

 

Water

 

 

14,734

 

 

14,606

 

 

58,466

 

 

56,760

 

 

 

 

Food Diagnostics Group

 

 

20,480

 

 

16,422

 

 

74,332

 

 

60,505

 

 

 

 

 

 

Total

 

$

192,209

 

$

166,970

 

$

739,117

 

$

638,095

 

 

 

Gross Profit:

 

 

Companion Animal Group

 

$

74,524

 

$

65,396

 

$

297,999

 

$

250,409

 

 

 

 

Water

 

 

9,588

 

 

9,951

 

 

38,441

 

 

38,277

 

 

 

 

Food Diagnostics Group

 

 

12,607

 

 

9,569

 

 

44,760

 

 

34,214

 

 

 

 

Other

 

 

(450

)

 

—  

 

 

(1,671

)

 

—  

 

 

 

 

 

 

Total

 

$

96,269

 

$

84,916

 

$

379,529

 

$

322,900

 

 

 

Income from Operations:

 

 

Companion Animal Group

 

$

22,219

 

$

21,369

 

$

100,760

 

$

82,970

 

 

 

 

Water

 

 

6,280

 

 

6,653

 

 

25,762

 

 

25,974

 

 

 

 

Food Diagnostics Group

 

 

5,459

 

 

3,038

 

 

18,024

 

 

9,894

 

 

 

 

Other

 

 

(4,488

)

 

(876

)

 

(16,613

)

 

(3,507

)

 

 

 

 

 

Total

 

$

29,470

 

$

30,184

 

$

127,933

 

$

115,331

 

 

 

Gross Profit (as a percentage of revenue):

 

 

Companion Animal Group

 

 

47.5

%

 

48.1

%

 

49.1

%

 

48.1

%

 

 

 

Water

 

 

65.1

%

 

68.1

%

 

65.7

%

 

67.4

%

 

 

 

Food Diagnostics Group

 

 

61.6

%

 

58.3

%

 

60.2

%

 

56.5

%

Income from Operations
(as a percentage of revenue):

 

 

Companion Animal Group

 

 

14.2

%

 

15.7

%

 

16.6

%

 

15.9

%

 

 

 

Water

 

 

42.6

%

 

45.5

%

 

44.1

%

 

45.8

%

 

 

 

Food Diagnostics Group

 

 

26.7

%

 

18.5

%

 

24.2

%

 

16.4

%


IDEXX Announces Fourth Quarter Results
January 26, 2007
Page 10 of 13

IDEXX Laboratories, Inc. and Subsidiaries
Revenues by Product and Service Categories
Amounts in thousands (Unaudited)

 

 

 

Three Months Ended

 

 

 

 

 

 

 

 

Dec. 31,
2006

 

Dec. 31,
2005

 

Dollar
Change

 

Percentage
Change

 

Percentage
Change from
Currency(1)

 

Percentage
Change from
Acquisitions(2)

 

Percentage
Change Net of
Acquisitions
and Currency
Changes

 

 

 

Net CAG Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Instruments and consumables

 

$

64,986

 

$

59,181

 

$

5,805

 

 

9.8

%

 

2.7

%

 

—  

 

 

7.1

%

 

Rapid assay products

 

 

25,724

 

 

22,815

 

 

2,909

 

 

12.8

%

 

0.8

%

 

4.4

%

 

7.6

%

 

Laboratory and consulting services

 

 

47,827

 

 

39,527

 

 

8,300

 

 

21.0

%

 

3.0

%

 

5.1

%

 

12.9

%

 

Practice information systems and digital radiography

 

 

13,663

 

 

10,763

 

 

2,900

 

 

26.9

%

 

1.1

%

 

—  

 

 

25.8

%

 

Pharmaceutical products

 

 

4,795

 

 

3,656

 

 

1,139

 

 

31.2

%

 

—  

 

 

—  

 

 

31.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net CAG revenue

 

 

156,995

 

 

135,942

 

 

21,053

 

 

15.5

%

 

2.3

%

 

2.2

%

 

11.0

%

Net Water Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Water

 

 

14,734

 

 

14,606

 

 

128

 

 

0.9

%

 

3.0

%

 

—  

 

 

-2.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net FDG Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Production animal products

 

 

16,630

 

 

12,569

 

 

4,061

 

 

32.3

%

 

7.1

%

 

—  

 

 

25.2

%

 

Dairy testing products

 

 

3,850

 

 

3,853

 

 

(3

)

 

-0.1

%

 

3.0

%

 

—  

 

 

-3.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net FDG revenue

 

 

20,480

 

 

16,422

 

 

4,058

 

 

24.7

%

 

6.2

%

 

—  

 

 

18.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Revenue:

 

$

192,209

 

$

166,970

 

$

25,239

 

 

15.1

%

 

2.7

%

 

1.8

%

 

10.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)  Represents the percentage change in revenue attributed to the effect of changes in currency rates from the three months ended December 31, 2005 to the three months ended December 31, 2006.

 

(2)  Represents the percentage change in revenue attributed to incremental revenues from businesses acquired since October 2005 during the three months ended December 31, 2005 compared to the three months ended December 31, 2006.


IDEXX Announces Fourth Quarter Results
January 26, 2007
Page 11 of 13

IDEXX Laboratories, Inc. and Subsidiaries
Revenues by Product and Service Categories
Amounts in thousands (Unaudited)

 

 

 

Twelve Months Ended

 

 

 

 

 

 

 

 

Dec. 31
2006

 

Dec. 31
2005

 

Dollar
Change

 

Percentage
Change

 

Percentage
Change from
Currency(1)

 

Percentage
Change from
Acquisitions(2)

 

Percentage
Change Net of
Acquisitions
and Currency
Changes

 

 

 

Net CAG Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Instruments and consumables

 

$

242,312

 

$

217,537

 

$

24,775

 

 

11.4

%

 

0.5

%

 

—  

 

 

10.9

%

 

Rapid assay products

 

 

114,536

 

 

100,255

 

 

14,281

 

 

14.2

%

 

-0.1

%

 

1.6

%

 

12.7

%

 

Laboratory and consulting services

 

 

187,114

 

 

156,425

 

 

30,689

 

 

19.6

%

 

0.2

%

 

4.5

%

 

14.9

%

 

Practice information systems and digital radiography

 

 

44,427

 

 

32,589

 

 

11,838

 

 

36.3

%

 

0.8

%

 

10.6

%

 

24.9

%

 

Pharmaceutical products

 

 

17,930

 

 

14,024

 

 

3,906

 

 

27.9

%

 

—  

 

 

—  

 

 

27.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net CAG revenue

 

 

606,319

 

 

520,830

 

 

85,489

 

 

16.4

%

 

0.3

%

 

2.3

%

 

13.8

%

Net Water Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Water

 

 

58,466

 

 

56,760

 

 

1,706

 

 

3.0

%

 

0.8

%

 

—  

 

 

2.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net FDG Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Production animal products

 

 

58,940

 

 

44,945

 

 

13,995

 

 

31.1

%

 

0.9

%

 

—  

 

 

30.2

%

 

Dairy testing products

 

 

15,392

 

 

15,560

 

 

(168

)

 

-1.1

%

 

-0.1

%

 

—  

 

 

-1.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net FDG revenue

 

 

74,332

 

 

60,505

 

 

13,827

 

 

22.9

%

 

0.7

%

 

—  

 

 

22.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Revenue:

 

 

$

739,117

 

$

638,095

 

$

101,022

 

 

15.8

%

 

0.4

%

 

1.8

%

 

13.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)  Represents the percentage change in revenue attributed to the effect of changes in currency rates from the twelve months ended December 31, 2005 to the twelve months ended December 31, 2006.

 

(2)  Represents the percentage change in revenue attributed to incremental revenues from businesses acquired since January 2005 during the twelve months ended December 31, 2005 compared to the twelve months ended December 31, 2006.


IDEXX Announces Fourth Quarter Results
January 26, 2007
Page 12 of 13

IDEXX Laboratories, Inc. and Subsidiaries
Consolidated Balance Sheet
Amounts in thousands (Unaudited)

 

 

 

December 31,
2006

 

December 31,
2005

 

 

 

Assets:

Current Assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

61,666

 

$

67,151

 

 

Short-term investments

 

 

35,000

 

 

65,580

 

 

Accounts receivable, net

 

 

81,389

 

 

71,688

 

 

Inventories

 

 

95,996

 

 

69,369

 

 

Other current assets

 

 

28,212

 

 

25,457

 

 

 

 

Total current assets

 

 

302,263

 

 

299,245

 

 

 

 

Property and equipment, at cost

 

 

191,538

 

 

142,777

 

 

Less: accumulated depreciation

 

 

91,910

 

 

77,080

 

 

 

 

Property and equipment, net

 

 

99,628

 

 

65,697

 

 

 

 

Other long-term assets, net

 

 

157,669

 

 

125,734

 

 

 

 

Total assets

 

$

559,560

 

$

490,676

 

 

 

Liabilities and Stockholders’ Equity:

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

24,374

 

$

19,842

 

 

Accrued expenses

 

 

90,315

 

 

78,208

 

 

Current portion of long-term debt

 

 

678

 

 

551

 

 

Deferred revenue

 

 

8,976

 

 

7,965

 

 

 

 

Total current liabilities

 

 

124,343

 

 

106,566

 

 

 

 

Long-term debt, net of current portion

 

 

6,447

 

 

—  

 

 

Other long-term liabilities

 

 

18,909

 

 

14,800

 

 

 

 

Total long-term liabilities

 

 

25,356

 

 

14,800

 

 

 

 

Partner's interest in subsidiary

 

 

—  

 

 

300

 

 

 

 

Stockholders’ Equity:

 

 

 

 

 

 

 

 

Common stock

 

 

4,662

 

 

4,594

 

 

Additional paid-in capital

 

 

479,993

 

 

437,394

 

 

Deferred stock units

 

 

1,852

 

 

1,316

 

 

Retained earnings

 

 

490,614

 

 

396,936

 

 

Treasury stock, at cost

 

 

(577,826

)

 

(472,096

)

 

Accumulated other comprehensive income

 

 

10,566

 

 

866

 

 

 

 

Total stockholders’ equity

 

 

409,861

 

 

369,010

 

 

 

 

Total liabilities and stockholders’ equity

 

$

559,560

 

$

490,676

 

 

 

IDEXX Laboratories, Inc. and Subsidiaries
Key Balance Sheet Information (Unaudited)

 

 

 

December 31,
2006

 

December 31,
2005

 

 

 

Key Balance Sheet

Total cash, cash equivalents and investments (in thousands)

 

$

96,666

 

$

132,731

 

Information:

Days sales outstanding

 

 

38

 

 

38

 

 

Inventory turns

 

 

1.9

 

 

2.4

 


IDEXX Announces Fourth Quarter Results
January 26, 2007
Page 13 of 13

IDEXX Laboratories, Inc. and Subsidiaries
Consolidated Statement of Cash Flows
Amounts in thousands (Unaudited)

 

 

 

Twelve Months Ended

 

 

 

 

 

 

 

 

December 31,
2006

 

December 31,
2005

 

 

 

Operating:

Cash Flows from Operating Activities:

 

 

 

 

 

 

 

 

Net income

 

$

93,678

 

$

78,254

 

 

Non-cash charges

 

 

25,551

 

 

27,553

 

 

Changes in current assets and liabilities, net of acquisitions and disposals

 

 

(9,403

)

 

10,745

 

 

 

 

Net cash provided by operating activities

 

$

109,826

 

$

116,552

 

 

 

Investing:

Cash Flows from Investing Activities:

 

 

 

 

 

 

 

 

Decrease in investments, net

 

 

30,655

 

 

44,261

 

 

Purchase of property and equipment

 

 

(32,331

)

 

(24,199

)

 

Purchase of land and buildings

 

 

(12,084

)

 

—  

 

 

Net proceeds from sale of land and buildings

 

 

—  

 

 

2,751

 

 

Acquisition of businesses and intangible assets

 

 

(25,220

)

 

(7,604

)

 

Acquisition of equipment leased to customers

 

 

(1,720

)

 

(2,615

)

 

 

 

Net cash provided (used) by investing activities

 

$

(40,700

)

$

12,594

 

 

 

Financing:

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

 

Repayment of notes payable

 

 

(877

)

 

(2,057

)

 

Purchase of treasury stock

 

 

(105,711

)

 

(123,769

)

 

Proceeds from the exercise of stock options

 

 

20,922

 

 

18,841

 

 

Tax benefit from exercise of stock options

 

 

9,407

 

 

—  

 

 

 

 

Net cash used by financing activities

 

$

(76,259

)

$

(106,985

)

 

 

 

Net effect of exchange rate changes

 

 

1,648

 

 

(2,166

)

 

 

 

Net increase (decrease) in cash and cash equivalents

 

 

(5,485

)

 

19,995

 

 

 

 

Cash and cash equivalents, beginning of period

 

 

67,151

 

 

47,156

 

 

 

 

Cash and cash equivalents, end of period

 

$

61,666

 

$

67,151

 

 

 

IDEXX Laboratories, Inc. and Subsidiaries
Free Cash Flow (Unaudited)

 

 

 

Twelve Months Ended

 

 

 

 

 

 

 

 

December 31,
2006

 

December 31,
2005

 

 

 

Free Cash Flow:

Net cash provided by operating activities

 

$

109,826

 

$

116,552

 

 

Financing cash flows attributable to tax benefits from exercise of stock options

 

 

9,407

 

 

—  

 

 

Purchase of fixed assets

 

 

(44,415

)

 

(24,199

)

 

Acquisition of equipment leased to customers

 

 

(1,720

)

 

(2,615

)

 

 

 

Free cash flow

 

$

73,098

 

$

89,738

 

 

 

 

Free cash flow indicates the cash generated from operations and tax benefits attributable to stock option exercises, reduced by investments in fixed assets. We feel free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in fixed assets that are required to operate the business.  We believe this is a common financial measure useful to further evaluate the results of operations.

IDEXX Laboratories, Inc. and Subsidiaries
Common Stock Repurchases

 

 

 

Three Months Ended

 

Twelve Months Ended

 

 

 

 

 

 

 

 

 

December 31,
2006

 

December 31,
2005

 

December 31,
2006

 

December 31,
2005

 

 

 

 

Share repurchases during the period

 

 

142,800

 

 

499,700

 

 

1,337,700

 

 

1,992,900

 

 

Average price paid per share

 

$

83.18

 

$

69.98

 

$

79.02

 

$

62.11

 

 

Shares remaining under repurchase authorization as of December 31, 2006

 

 

 

 

 

 

 

 

714,630